DarioHealth Corp.: DarioHealth Reports Second Quarter 2026 Financial Results
DarioHealth Corp. (NASDAQ: DRIO) reported Q2 2026 revenue of $5.2 million, down from $5.6 million in Q1 2026, citing discontinuation of some pharmaceutical-related business. Gross margin rose to 62% (from 57% in Q1 2026). Operating loss improved 30% YoY and 11% QoQ. Pro forma cash was $36.8 million after July 2026 at-the-market financing.
How this was made
The 30-second read
Why it matters
Q2 results show margin expansion (62% gross margin) and lower operating loss alongside a strengthened cash position after July registered direct financing. Commercial highlights include new Fortune 50 and insurer wins via Amwell, expansion of an existing top-5 national health plan, and a new provider-backed integrated GLP-1 program through Beluga Health.
Market read
Traders can reassess near-term risk/reward based on profitability improvement, cash runway, and the monetization timeline for newly signed payer and provider-backed initiatives.
What to watch
The article emphasizes expected ARR contribution timing (end of 2026 and ramp into 2027) and provider-backed rollout, but provides limited quantitative guidance on how quickly these wins translate into recognized revenue.
Background
DarioHealth is an AI-powered chronic-condition management platform selling via B2B2C and channel partners, and is expanding into provider-backed clinical care delivery.
Ticker impact
DarioHealth reported Q2 2026 results with revenue $5.2M, gross margin 62%, and a $36.8M pro forma cash balance after July ATM financing.
Likely positive bias into the Aug 11 call, with follow-through dependent on whether management quantifies ARR ramp and provider-backed program monetization.
The article discloses concrete financial datapoints (revenue, margins, operating loss, cash) plus specific customer/channel expansions and a new provider-backed GLP-1 offering, but it does not provide full-year guidance or detailed ARR trajectory beyond expected contribution windows.
Market effects
Reinforces the chronic-care digital health model shifting toward provider-backed care and AI-enabled engagement, which can influence sentiment for similar healthcare software names.
Primarily US-focused healthcare payer/provider ecosystem; limited direct regional spillover implied.
Low direct global relevance beyond broader digital health investment sentiment.
Counterpoint
Revenue declined sequentially ($5.2M vs $5.6M) and the pharma-related discontinuation suggests underlying demand or mix issues that may cap near-term growth despite margin improvement.
Key entities
- companyDarioHealth Corp.
NASDAQ-listed AI-powered chronic care technology company reporting Q2 2026 financial results and commercial progress.
- partnerBeluga Health
Care delivery infrastructure provider enabling Dario’s provider-backed clinical care expansion.
- channel_partnerAmwell
Channel partnership used to sign a new health insurer with a stronghold in Arizona.
- channel_partnerSolera
Channel partner that expanded its contract to add Dario’s hypertension program across its member base.
